Launch Date
10/11/2022 at 4:00 am EST
Credit Amount
0.5
Credit Expires
12/31/2025
The incidence of, and death from, multiple myeloma (MM) is 50% more in men than in women and over twice among Black people compared with White people, in spite of the fact that Black patients are more likely than White patients to have MM with a favorable risk profile. Much of these disparities in outcomes can be mitigated by providing equitable access to therapy. Among data from 9 previously published clinical trials in patients with newly diagnosed MM, adverse demographic and clinical factors were associated with inferior survival, but race was not. One of the key access points to evidence-based medicine is clinical trials, and unfortunately, non-White patients are underrepresented in clinical trials. As such, greater enrollment of non-White patients into clinical trials needs to be a priority. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, clinicians can help reduce this disparity by improving access to evidence-based medicine, including triplet therapies, stem cell transplants, CAR T-cell therapies, and clinical trials.
In this CME Outfitters podcast, expert faculty will review recent data and discuss the sweeping impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve multiple myeloma treatment.
At the end of this CME/CE activity, participants should be able to identify and describe the influence of bias, disparities, and inequities on multiple myeloma care.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and dietitians, specializing in oncology, hematology, or involved in treating patients with multiple myeloma
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Mitchell reports the following financial relationships:
Dr. Mikhael reports the following financial relationships:
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at (877) CME-PROS or (877) 263-7767.
PD-085-101122-57